Document Detail

Vernakalant hydrochloride to treat atrial fibrillation.
MedLine Citation:
PMID:  24617913     Owner:  NLM     Status:  Publisher    
Introduction: Intravenous vernakalant (Brinavess) has been developed and approved in Europe as a safe and efficacious drug to rapidly convert recent onset atrial fibrillation to sinus rhythm in patients with no minimal or structural heart disease. Areas covered: The pharmacology of vernakalant and the pivotal Phase II and III clinical trials undertaken during its development are discussed with regard to safety and efficacy. An extensive PubMed search was used to identify suitable papers. Expert opinion: As yet, there is no evidence of benefit over and above intravenous flecainide or propafenone for patients in whom vernakalant has a class 1a recommendation. As such, it is likely to be most useful in centres where only amiodarone is available.
Richard A Brown; Yee Cheng Lau; Gregory Yh Lip
Related Documents :
8886573 - Helicobacter pylori-negative duodenal and pyloric ulcer: role of nsaids.
580163 - The incidence of urolithiasis in peptic ulcer patients.
18222013 - Gallbladder disease in patients with primary sclerosing cholangitis.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-3-11
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  -     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2014 Mar 
Date Detail:
Created Date:  2014-3-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Assessment of school wellness policies implementation by benchmarking against diffusion of innovatio...
Next Document:  Wetting Transitions of Water on Graphite and Graphene.